Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Draft US bill on payments to physicians imposes strict disclosure rules

This article was originally published in RAJ Devices

Executive Summary

Senators Charles Grassley (Republican - Iowa) and Herb Kohl (Democrat - Wisconsin) have reintroduced legislation that seeks to impose strict rules for disclosing financial relationships between medical device companies and doctors, including requiring the creation of a national registry of industry payments to physicians1. The Physician Payments Sunshine Act now has a lower payment disclosure threshold - namely requiring drug and device companies to publicly report the payments, consulting fees, honoraria and other “transfers” they give to doctors over $100 every year. In the previous version of the bill (S 2029), the threshold was $5002. The information would be posted on a federal website for public viewing in 2011.

You may also be interested in...



COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

BioNTech Looks To AI Partnership To Accelerate Drug Discovery

The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.

Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel